<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04510922</url>
  </required_header>
  <id_info>
    <org_study_id>Lundbeck-TOMs-OH-001</org_study_id>
    <nct_id>NCT04510922</nct_id>
  </id_info>
  <brief_title>Lundbeck TOMs Orthostatic Hypotension</brief_title>
  <official_title>Technology-Based Objective Measures for Gait and Postural Assessment in Parkinson Disease Patients With Orthostatic Hypotension: Feasibility and Effect-Size Finding Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alberto Espay, MD, MSc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lundbeck LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Orthostatic hypotension (OH), which consists in a significant reduction in blood pressure&#xD;
      levels upon standing from a seated position, may affect approximately one in three patients&#xD;
      with Parkinson's disease (PD). It usually presents as dizziness, lightheadedness, feeling&#xD;
      faint, or feeling like you might black out while standing. This can significantly impact the&#xD;
      quality of life (QoL) of PD patients, resulting in difficulties with balance, walking, and&#xD;
      increased risk of falls. The main aim of this study is to evaluate whether the use of&#xD;
      technological devices (a computerized system for analyzing abnormalities in walking in&#xD;
      clinical settings and a wearable sensor to detect changes in postural unsteadiness in the&#xD;
      home environment) may improve the detection of complications and the response to medical&#xD;
      therapies for OH in patients with PD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 11, 2019</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Orthostatic Hypotension Questionnaire (OHQ) Score</measure>
    <time_frame>1 month</time_frame>
    <description>Orthostatic Hypotension Symptom Assessment (OHSA) and Orthostatic Hypotension Daily Activities Scale (OHDAS) 10 items measured on a Likert-scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tinetti Score</measure>
    <time_frame>1 month</time_frame>
    <description>Ordinal scale ranging 0-2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PDQ-39 score</measure>
    <time_frame>1 month</time_frame>
    <description>39 items ranked on a 5-point ordinal scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gait analysis - stride length</measure>
    <time_frame>1 month</time_frame>
    <description>Measured in cm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gait analysis - single leg stance time</measure>
    <time_frame>1 month</time_frame>
    <description>Measured in seconds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gait analysis - dynamic stability index</measure>
    <time_frame>1 month</time_frame>
    <description>Measured in IMU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gait analysis - gait velocity</measure>
    <time_frame>1 month</time_frame>
    <description>Measured in seconds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postural analysis - postural sway</measure>
    <time_frame>1 month</time_frame>
    <description>Measured in mm/sec on the X and Y-axis</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Orthostatic Hypotension</condition>
  <condition>Idiopathic Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Droxidopa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100-600mg droxidopa TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Droxidopa 100 MG [Northera]</intervention_name>
    <description>droxidopa taken three times a day titrated up to a maximum of 600 mg.</description>
    <arm_group_label>Droxidopa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of idiopathic Parkinson's Disease, meeting UK Brain Bank criteria for at&#xD;
             least 3 years&#xD;
&#xD;
          -  Hoehn and Yahr (H&amp;Y) stage I-III&#xD;
&#xD;
          -  Age between 30 and 80 years old (both inclusive)&#xD;
&#xD;
          -  Stable dosage of dopaminergic medications for at least 4 weeks&#xD;
&#xD;
          -  Orthostatic Hypotension, defined as a fall in systolic BP ≥ 20 mmHg or diastolic BP ≥&#xD;
             10 mmHg within 3 minutes of standing&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes mellitus or other diseases potentially associated with autonomic dysfunction&#xD;
&#xD;
          -  Treatment with antihypertensive drugs or with alpha-adrenergic antagonists&#xD;
&#xD;
          -  Cognitive impairment, defined as a score &lt; 24 at the Montreal Cognitive Assessment&#xD;
             (MoCA)&#xD;
&#xD;
          -  Any atypical signs lowering the diagnostic certainty for PD&#xD;
&#xD;
          -  Lack of postural reflex defined as a score &gt; 2 at the MDS-UPDRS item 3.12 (recover at&#xD;
             the pull test)&#xD;
&#xD;
          -  Severe levodopa induced dyskinesia, defined as an MDS-UPDRS item 4.2 &gt; 2 (functional&#xD;
             impact of dyskinesia)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RM. Prevalence of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2011 Dec;17(10):724-9. doi: 10.1016/j.parkreldis.2011.04.016. Epub 2011 May 14. Review.</citation>
    <PMID>21571570</PMID>
  </reference>
  <reference>
    <citation>Palma JA, Gomez-Esteban JC, Norcliffe-Kaufmann L, Martinez J, Tijero B, Berganzo K, Kaufmann H. Orthostatic hypotension in Parkinson disease: how much you fall or how low you go? Mov Disord. 2015 Apr 15;30(5):639-45. doi: 10.1002/mds.26079. Epub 2015 Feb 12.</citation>
    <PMID>25678194</PMID>
  </reference>
  <reference>
    <citation>Senard JM, Raï S, Lapeyre-Mestre M, Brefel C, Rascol O, Rascol A, Montastruc JL. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997 Nov;63(5):584-9.</citation>
    <PMID>9408097</PMID>
  </reference>
  <reference>
    <citation>Tan LC, Tan AK, Tjia HT. The profile of hospitalised patients with Parkinson's disease. Ann Acad Med Singap. 1998 Nov;27(6):808-12.</citation>
    <PMID>10101555</PMID>
  </reference>
  <reference>
    <citation>Woodford H, Walker R. Emergency hospital admissions in idiopathic Parkinson's disease. Mov Disord. 2005 Sep;20(9):1104-8.</citation>
    <PMID>15884038</PMID>
  </reference>
  <reference>
    <citation>Vossius C, Nilsen OB, Larsen JP. Parkinson's disease and hospital admissions: frequencies, diagnoses and costs. Acta Neurol Scand. 2010 Jan;121(1):38-43. doi: 10.1111/j.1600-0404.2009.01239.x. Epub 2009 Sep 10.</citation>
    <PMID>19744137</PMID>
  </reference>
  <reference>
    <citation>Kaufmann H, Malamut R, Norcliffe-Kaufmann L, Rosa K, Freeman R. The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res. 2012 Apr;22(2):79-90. doi: 10.1007/s10286-011-0146-2. Epub 2011 Nov 2.</citation>
    <PMID>22045363</PMID>
  </reference>
  <reference>
    <citation>Merola A, Romagnolo A, Rosso M, Lopez-Castellanos JR, Wissel BD, Larkin S, Bernardini A, Zibetti M, Maule S, Lopiano L, Espay AJ. Orthostatic hypotension in Parkinson's disease: Does it matter if asymptomatic? Parkinsonism Relat Disord. 2016 Dec;33:65-71. doi: 10.1016/j.parkreldis.2016.09.013. Epub 2016 Sep 10.</citation>
    <PMID>27641792</PMID>
  </reference>
  <reference>
    <citation>Hubble RP, Naughton GA, Silburn PA, Cole MH. Wearable sensor use for assessing standing balance and walking stability in people with Parkinson's disease: a systematic review. PLoS One. 2015 Apr 20;10(4):e0123705. doi: 10.1371/journal.pone.0123705. eCollection 2015. Review.</citation>
    <PMID>25894561</PMID>
  </reference>
  <reference>
    <citation>Tinetti ME. Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc. 1986 Feb;34(2):119-26.</citation>
    <PMID>3944402</PMID>
  </reference>
  <reference>
    <citation>Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing. 1997 Sep;26(5):353-7.</citation>
    <PMID>9351479</PMID>
  </reference>
  <reference>
    <citation>Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Rabbitt P. Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia. 1994 Sep-Oct;5(5):266-81.</citation>
    <PMID>7951684</PMID>
  </reference>
  <reference>
    <citation>Karrasch M, Laatu S, Martikainen K, Marttila R. CERAD test performance and cognitive impairment in Parkinson's disease. Acta Neurol Scand. 2013 Dec;128(6):409-13. doi: 10.1111/ane.12138. Epub 2013 May 14.</citation>
    <PMID>23668316</PMID>
  </reference>
  <reference>
    <citation>Espay AJ, Bonato P, Nahab FB, Maetzler W, Dean JM, Klucken J, Eskofier BM, Merola A, Horak F, Lang AE, Reilmann R, Giuffrida J, Nieuwboer A, Horne M, Little MA, Litvan I, Simuni T, Dorsey ER, Burack MA, Kubota K, Kamondi A, Godinho C, Daneault JF, Mitsi G, Krinke L, Hausdorff JM, Bloem BR, Papapetropoulos S; Movement Disorders Society Task Force on Technology. Technology in Parkinson's disease: Challenges and opportunities. Mov Disord. 2016 Sep;31(9):1272-82. doi: 10.1002/mds.26642. Epub 2016 Apr 29. Review.</citation>
    <PMID>27125836</PMID>
  </reference>
  <reference>
    <citation>Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745-52. Review.</citation>
    <PMID>2841426</PMID>
  </reference>
  <reference>
    <citation>Lahrmann H, Cortelli P, Hilz M, Mathias CJ, Struhal W, Tassinari M. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol. 2006 Sep;13(9):930-6.</citation>
    <PMID>16930356</PMID>
  </reference>
  <reference>
    <citation>Dineen J, Freeman R. Autonomic Neuropathy. Semin Neurol. 2015 Aug;35(4):458-68. doi: 10.1055/s-0035-1558983. Epub 2015 Oct 6. Review.</citation>
    <PMID>26502768</PMID>
  </reference>
  <reference>
    <citation>Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. Erratum in: J Am Geriatr Soc. 2019 Sep;67(9):1991.</citation>
    <PMID>15817019</PMID>
  </reference>
  <reference>
    <citation>Jordan J, Biaggioni I. Diagnosis and treatment of supine hypertension in autonomic failure patients with orthostatic hypotension. J Clin Hypertens (Greenwich). 2002 Mar-Apr;4(2):139-45.</citation>
    <PMID>11927799</PMID>
  </reference>
  <reference>
    <citation>Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N; Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15;23(15):2129-70. doi: 10.1002/mds.22340.</citation>
    <PMID>19025984</PMID>
  </reference>
  <reference>
    <citation>O'Sullivan JD, Said CM, Dillon LC, Hoffman M, Hughes AJ. Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function. Mov Disord. 1998 Nov;13(6):900-6.</citation>
    <PMID>9827613</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 9, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Alberto Espay, MD, MSc</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Hypotension, Orthostatic</mesh_term>
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Droxidopa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

